<unk>  (also abbreviated EBV-associated lymphoproliferative<unk>  or EBV+ LPD) are a group of disorders in which one or more types of lymphoid cells (a type of white blood cell), i.e. B cells, T cells, NK cells, and histiocytic-dendritic cells, are infected with the<unk> –Barr<unk>  (EBV). This causes the infected cells to divide excessively, and is<unk>  with the development of various non-cancerous, pre-cancerous, and cancerous lymphoproliferative disorders (LPDs). These LPDs include the well-known disorder occurring during the initial infection with the EBV, infectious mononucleosis, and the large number of subsequent disorders that may occur thereafter. The<unk>  is usually involved in the development and/or progression of these LPDs although in some cases it may be an "innocent" bystander, i.e. present in, but not contributing to, the<unk>  EBV-associated LPDs are a subcategory of EBV-associated<unk> . Non-LPD that have significant percentages of cases<unk>  with EBV infection (see<unk> –Barr<unk>  infection) include the immune disorders of multiple sclerosis and systemic lupus erythematosus; malignancies such as stomach cancers, soft tissue sarcomas, leiomyosarcoma, and undifferentiated nasopharyngeal cancer; the childhood disorders of Alice in Wonderland syndrome; and acute cerebellar ataxia. About 95% of the world's population is infected with EBV. During the initial infection, the<unk>  may cause infectious mononucleosis, only minor non-specific symptoms, or no symptoms. Regardless of this, the<unk>  enters a latency phase in its host and the infected individual becomes a lifetime asymptomatic carrier of EBV. Weeks, months, years, or decades thereafter, a small percentage of these carriers, particularly those with an immunodeficiency, develop an EBV+ LPD. Worldwide, EBV infection is<unk>  with 1% to 1.5% of all cancers. The vast majority of these EBV-associated cancers are LPD. The non-malignant, premalignant, and malignant forms of EBV+ LPD have a huge impact on world health. The classification and nomenclature of the LPD reported here follow the revisions made by the World Health Organization in 2016. This classification divides EBV+ LPD into five categories: EBV-associated reactive lymphoid proliferations, EBV-associated B cell lymphoproliferative disorders, EBV-associated NK/T cell lymphoproliferative disorders, EBV-associated immunodeficiency-related lymphoproliferative disorders, and EBV-associated histiocytic-dendritic disorders.
Epstein–Barr virus–associated lymphoproliferative diseases
Tuberculosis in relation to HIV
AIDS-related lymphoma
HIV/AIDS
Epstein–Barr virus infection
AIDS-related complex
HIV superinfection
Autoimmune lymphoproliferative syndrome